How will NICE fare in a post-Brexit world?
pharmaphorum
MAY 14, 2021
This article appears in our digital magazine, Deep Dive: Market Access 2021. Practically though, there are risks of additional processes and requirements (and expense) for pharmaceutical companies. NICE has a global reputation as a pioneering HTA – but is that influence at risk now that the UK has left the EU?
Let's personalize your content